Stereotaxis to Highlight Efficiency, Efficacy and Safety of Its Technology at Cardiostim 2014
June 16 2014 - 6:30AM
Stereotaxis, Inc. (Nasdaq:STXS) today announced that it will
participate in Cardiostim 2014, the biennial scientific congress of
the European Heart Rhythm Association (EHRA), to be held June
18-21, 2014 in Nice, France. The event represents the largest
conference attended by the Company in Europe, expected to draw more
than 5,600 electrophysiology (EP) and cardiology professionals from
Europe and around the world.
"Building on a successful Heart Rhythm Society session in the
U.S., we are excited to highlight our product advancements and the
procedure efficiency, proven outcomes and unmatched safety profile
of our technology to the EHRA congress," said William C. Mills,
Stereotaxis Chief Executive Officer.
More than 500 EP physicians worldwide currently rely on
Stereotaxis technology, with the largest volume of Stereotaxis
procedures performed in the European Union, particularly in the
treatment of atrial fibrillation. At Cardiostim (Booth C16), the
Company will introduce participants to its enhanced user interface,
which features Ablation History, a graphical display enabling
physicians to retrace their ablation-related activity and
potentially identify gaps in lesion lines on a real-time basis. The
new feature is designed to arm physicians with visual intelligence
on the applied treatment in order to improve procedure efficiency
and outcomes. In addition, the Company will share new internal data
substantiating comparable procedure times with manual methods for
proficient Stereotaxis users.
During a lunch symposium on June 19, Stereotaxis physician users
will present on "Efficiency Effectively Applied," speaking to their
personal success with implementing the Company's magnetic
navigation platform in their EP practices. Moderated by Professor
Gerhard Hindricks of Herzzentrum Leipzig in Germany and Professor
Hiroshi Nakagawa of the University of Oklahoma Health Sciences
Center, the event's speakers include Dr. Bruno Schwagten (ZNA
Middelheim, Middelheim, Belgium), Dr. Erik Wissner (Asklepios
Hospital St. Georg, Hamburg, Germany) and Professor Pekka
Raatikainen (Tampere University Hospital, Tampere, Finland).
In addition, two scientific sessions will feature an abstract
and poster related to Stereotaxis technologies:
- "Catheter Positioning During Pulmonary Vein Isolation Easier
with Magnetic than Manual Techniques;" Dr. Gabriel Latcu, Princess
Grace Medical Centre, Monaco
- "Retrograde AF Approach with Stereotaxis;" Dr. Christine Lemes,
Asklepios Hospital St. Georg, Hamburg, Germany
About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in
the development of robotic cardiology instrument navigation systems
designed to enhance the treatment of arrhythmias and coronary
disease, as well as information management solutions for the
interventional lab. Over 100 issued patents support the Stereotaxis
platform, which helps physicians around the world provide
unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis' core Epoch™ Solution
includes the Niobe® ES Remote Magnetic Navigation system, the
Odyssey® portfolio of lab optimization, networking and patient
information management systems and the Vdrive™ Robotic Navigation
system and consumables.
The core components of Stereotaxis systems have received
regulatory clearance in the U.S., European Union, Canada, China,
Japan and elsewhere. The V-Sono™ ICE catheter manipulator has
received U.S. clearance, and the V-Loop™ variable loop catheter
manipulator and V-CAS™ catheter advancement system have been
submitted for review by the U.S. Food and Drug Administration. For
more information, please visit www.stereotaxis.com
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words
"believe," "estimate," "project," "expect" or similar expressions.
Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or
contribute to such differences include, but are not limited to, the
Company's ability to raise additional capital on a timely basis and
on terms that are acceptable, its ability to continue to manage
expenses and cash burn rate at sustainable levels, its ability to
continue to work with lenders to extend, repay or refinance
indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its systems and the timing of such purchases, the outcome
of various shareholder litigation filed against Stereotaxis,
competitive factors, changes resulting from the recently enacted
healthcare reform in the U.S., including changes in government
reimbursement procedures, dependence upon third-party vendors,
timing of regulatory approvals, and other risks discussed in the
Company's periodic and other filings with the Securities and
Exchange Commission. By making these forward-looking statements,
the Company undertakes no obligation to update these statements for
revisions or changes after the date of this release. There can be
no assurance that the Company will recognize revenue related to its
purchase orders and other commitments in any particular period or
at all because some of these purchase orders and other commitments
are subject to contingencies that are outside of the Company's
control. In addition, these orders and commitments may be revised,
modified, delayed or canceled, either by their express terms, as a
result of negotiations, or by overall project changes or
delays.
CONTACT: Company Contact:
Marty Stammer
Chief Financial Officer
314-678-6155
Investor Contact:
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
stxs@mkr-group.com